CABALETTA BIO, INC. Shareholders' Equity
CABALETTA BIO, INC. (CABA) had Shareholders' Equity of $210.59 million as of 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:StockholdersEquity · last filed 2026-08-13
- 2026-06-30: Stockholders' Equity Attributable to Parent $210.59M.
- 2026-03-31: Stockholders' Equity Attributable to Parent $103.31M.
- 2025-12-31: Stockholders' Equity Attributable to Parent $112.05M.
- 2025-09-30: Stockholders' Equity Attributable to Parent $139.47M.
| Period end | Stockholders' Equity Attributable to Parent |
|---|---|
| 2026-06-30 | $210.59M 10-Q · filed 2026-08-13 |
| 2026-03-31 | $103.31M 10-Q · filed 2026-08-13 |
| 2025-12-31 | $112.05M 10-Q · filed 2026-08-13 |
| 2025-09-30 | $139.47M 10-Q · filed 2025-11-10 |
| 2025-06-30 | $178.48M 10-Q · filed 2026-08-13 |
| 2025-03-31 | $121.55M 10-Q · filed 2026-08-13 |
| 2024-12-31 | $152.34M 10-Q · filed 2026-08-13 |
| 2024-09-30 | $174.24M 10-Q · filed 2025-11-10 |
| 2024-06-30 | $199.52M 10-Q · filed 2025-11-10 |
| 2024-03-31 | $221.72M 10-Q · filed 2025-11-10 |
| 2023-12-31 | $236.20M 10-K · filed 2026-03-23 |
| 2023-09-30 | $160.92M 10-Q · filed 2024-11-14 |
| 2023-06-30 | $174.14M 10-Q · filed 2024-11-14 |
| 2023-03-31 | $91.65M 10-Q · filed 2024-11-14 |
| 2022-12-31 | $104.52M 10-K · filed 2025-03-31 |
| 2022-09-30 | $85.87M 10-Q · filed 2023-11-09 |
| 2022-06-30 | $95.53M 10-Q · filed 2023-11-09 |
| 2022-03-31 | $106.72M 10-Q · filed 2023-11-09 |
| 2021-12-31 | $117.96M 10-K · filed 2024-03-21 |
| 2021-09-30 | $116.61M 10-Q · filed 2022-11-10 |
| 2021-06-30 | $101.33M 10-Q · filed 2022-11-10 |
| 2021-03-31 | $103.31M 10-Q · filed 2022-11-10 |
| 2020-12-31 | $109.54M 10-K · filed 2023-03-16 |
| 2020-09-30 | $117.50M 10-Q · filed 2021-11-01 |
| 2020-06-30 | $124.64M 10-Q · filed 2021-11-01 |
| 2020-03-31 | $131.71M 10-Q · filed 2021-11-01 |
| 2019-12-31 | $138.32M 10-K · filed 2022-03-17 |
| 2019-09-30 | -$26.07M 10-Q · filed 2020-11-10 |
| 2019-06-30 | -$21.99M 10-Q · filed 2020-11-10 |
| 2019-03-31 | -$19.05M 10-Q · filed 2020-11-10 |
| 2018-12-31 | -$10.69M 10-K · filed 2021-03-16 |
| 2018-09-30 | -$10.22M 10-Q · filed 2019-12-05 |
| 2018-06-30 | -$1.14M 10-Q · filed 2019-12-05 |
| 2017-12-31 | -$249.00K 10-K · filed 2020-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |